An innovative, noninvasive Israeli medication administered through the nose hopes to be a life-changer for people suffering acute spinal cord injuries – even helping them to walk again.

NurExone Biologic Inc. developed ExoPTEN, which treats damage to the nervous system, from a concept created by two members of its Scientific Advisory Board: Prof. Shulamit Levenberg of the Technion – Israel Institute of Technology and Prof. Daniel Offen from Tel Aviv University.

(Another member of the board is Prof. Gabriel Zeilig, the head of the National Spinal Cord Injury Rehabilitation Unit at Sheba Medical Center, Israel’s largest and globally renowned hospital.)

According to the World Health Organization, up to half a million people globally sustain a spinal cord injury every year, most from preventable causes such as road accidents or falls.

Furthermore, the WHO says, people suffering from spinal injuries are up to five times more likely to die prematurely and are less likely to complete their education or find economic stability.

The NurExone concept is two-fold: the medication’s active ingredient and its delivery via the nose.

Keep reading at